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Lyme arthritis, which is caused by the tick-borne 
spirochete Borrelia burgdorferi (1), can usually be 
treated successfully with 1 or 2 mo of oral anti-
biotic therapy, 2 or 4 wk of i.v. therapy, or both 
(2–4). However, in a small percentage of cases, 
proliferative synovitis of the knee continues for 
months or even several years after such courses 
of therapy, which is termed antibiotic-refractory 
Lyme arthritis. Although PCR results for B. 
burgdorferi DNA in joint fl  uid are usually positive 
before antibiotic therapy, they are frequently 
negative by the end of 2–3 mo of antibiotics (5), 
and they have been uniformly negative in syno-
vial samples obtained at synovectomy months 
after treatment (6). Thus, Lyme arthritis may 
continue after the near or total eradication of 
spirochetes from the joint, perhaps sustained by 
retained spirochetal antigens or an infection-
induced autoimmune response.
Most diseases with autoimmune features 
have HLA associations, particularly with class 
II MHC alleles. In our initial HLA study of 80 
patients with Lyme arthritis (7), which was 
performed from 1977 to 1987, an association 
was shown between chronic Lyme arthritis, 
the HLA-DR4 serologic specifi   city, and the 
lack of response to antibiotic therapy; a sec-
ondary association was noted with DR2. 
Thereafter, we began to determine HLA alleles 
in patients with Lyme arthritis using contem-
porary molecular techniques. In a preliminary 
analysis (Steere, A.C., and L.A. Baxter-Lowe. 
1998. Annual Meeting of the American Col-
lege of Rheumatology), patients with anti-
biotic-refractory arthritis had an increased 
frequency of alleles associated with the severity 
of rheumatoid arthritis (RA), primarily the 
DRB1*0401, 0101, or 0404 alleles; those with 
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An association has previously been shown between antibiotic-refractory Lyme arthritis, the 
human histocompatibility leukocyte antigen (HLA)–DR4 molecule, and T cell recognition of 
an epitope of Borrelia burgdorferi outer-surface protein A (OspA163–175). We studied the 
frequencies of HLA-DRB1-DQA1-DQB1 haplotypes in 121 patients with antibiotic-refrac-
tory or antibiotic-responsive Lyme arthritis and correlated these frequencies with in vitro 
binding of the OspA163–175 peptide to 14 DRB molecules. Among the 121 patients, the 
frequencies of HLA-DRB1-DQA1-DQB1 haplotypes were similar to those in control sub-
jects. However, when stratifi  ed by antibiotic response, the frequencies of DRB1 alleles in 
the 71 patients with antibiotic-refractory arthritis differed signifi  cantly from those in the 
50 antibiotic-responsive patients (log likelihood test, P = 0.006; exact test, P = 0.008; 
effect size, Wn = 0.38). 7 of the 14 DRB molecules (DRB1*0401, 0101, 0404, 0405, 
DRB5*0101, DRB1*0402, and 0102) showed strong to weak binding of OspA163–175, whereas 
the other seven showed negligible or no binding of the peptide. Altogether, 79% of the 
antibiotic-refractory patients had at least one of the seven known OspA peptide–binding 
DR molecules compared with 46% of the antibiotic-responsive patients (odds ratio = 4.4; 
P < 0.001). We conclude that binding of a single spirochetal peptide to certain DRB 
  molecules is a marker for antibiotic-refractory Lyme arthritis and might play a role in the 
pathogenesis of the disease.
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antibiotic-responsive arthritis more often had the 0801 or 
1101 alleles. Antibiotic-refractory patients have not been 
noted to have increased frequencies of the HLA-B27 allele 
(7), as in reactive arthritis, or the DRB1*0801 or DRB1*11 
alleles (Steere, A.C., and L.A. Baxter-Lowe. 1998. Annual 
Meeting of the American College of Rheumatology), as in 
pauciarticular juvenile RA (8).
Because the etiologic agent of Lyme arthritis is known, 
we have searched for a spirochetal antigen that may bind to 
certain HLA-DR molecules to trigger antibiotic-refractory 
arthritis. Cellular and humoral immune responses to B. burgdorferi 
outer-surface protein A (OspA) have been associated with 
this outcome (9–11). The spirochete expresses OspA primar-
ily in the mid-gut of the tick and not in the early mammalian 
infection (12). However, in a mouse model, the organism 
up-regulates this protein in infl  ammatory foci (13), which 
seems to be the case in the majority of patients with Lyme 
  arthritis. When archival serum samples were tested from 
  patients seen in the late 1970s before the use of antibiotic 
therapy for this infection, 70% of the patients had OspA anti-
body responses near the beginning of prolonged episodes of 
arthritis (9), and the levels of OspA antibody correlated di-
rectly with the severity and duration of arthritis (10). In con-
trast, there was no correlation between arthritis duration and 
antibody levels to eight other spirochetal proteins. In a study 
of T cell responses to spirochetal antigens, OspA was 
  preferentially recognized by T cell lines from patients with 
antibiotic-refractory Lyme arthritis but was only rarely 
  recognized by T cell lines from antibiotic-responsive patients 
(11). In contrast, the responses to four other spirochetal 
  proteins did not diff  er between these two groups.
As shown defi  nitively in DRB1*0401-transgenic mice, 
the immunodominant epitope of OspA presented by the 0401 
molecule was located at amino acids 163–175 (OspA163–175; 
  reference 14). When preliminary HLA data (Steere, A.C., 
and L.A. Baxter-Lowe. 1998. Annual Meeting of the Ameri-
can College of Rheumatology) were used to select fi  ve puri-
fi   ed HLA-DR molecules for in vitro OspA163–175 peptide 
binding studies, the DRB1*0401, 0101, and 0404 molecules, 
which were associated with antibiotic-refractory arthritis, 
bound the peptide, whereas the DRB1*0801 and 1101 mol-
ecules, which were more often found in antibiotic-responsive 
patients, did not (15). In addition, PBL from Lyme arthritis 
patients with the DRB1*0401, 0404, 0101, or 0102 alleles 
more often reacted with OspA163–175 than did PBL from 
  patients with other alleles, and patients in the former group 
were more likely to have an antibiotic-refractory course (16). 
Finally, as determined using tetramer reagents, DRB1*0401-
positive patients often had increased precursor frequencies of 
OspA163–175-reactive T cells in joint fl  uid (17). Thus, in 
  patients with certain DRB1 alleles, OspA163–175-reactive 
T cells were frequently concentrated in aff  ected joints, and 
these individuals were more likely to have an antibiotic-
  refractory course.
In this study, we determined HLA-DRB1, DQA1, and 
DQB1 haplotype and allele frequencies in 121 consecutive 
patients with Lyme arthritis (all were Caucasian) who were 
seen in our clinic over a 16-yr period. They were all treated 
with antibiotics according to the guidelines now recom-
mended by the Infectious Diseases Society of America (18). 
The haplotype and allele frequencies were fi  rst compared 
  between all 121 patients with Lyme arthritis and European-
American control subjects, and then between Lyme arthritis 
patients stratifi  ed by antibiotic response. Finally, in vitro 
binding of the OspA163–175 peptide to 14 recombinant or 
  purifi   ed DRB molecules was correlated with the clinical 
  outcome. Our results showed a marked correlation between 
antibiotic-refractory Lyme arthritis and HLA-DR molecules 
that bound the B. burgdorferi OspA163–175 epitope.
RESULTS
Haplotype frequencies in Lyme arthritis patients 
and control subjects
We fi  rst compared the frequencies of HLA-DRB1-DQA1-
DQB1 haplotypes (the most detailed genetic analysis) in 121 
Caucasian patients with Lyme arthritis (242 alleles) to the 
published frequencies of these haplotypes in 1,899 European-
American bone marrow donors (3,798 alleles; reference 19). 
The laboratory that determined the HLA profi  les in Lyme 
arthritis patients also participated in the typing of the control 
population. In these cases and control groups, 85 distinct 
haplotypes were identifi  ed, 30 of which were common 
enough for meaningful individual comparisons (Table I). 
When these haplotypes were compared between Lyme ar-
thritis patients and the control population, a diff  erence of 
borderline signifi   cance was found (log likelihood test, 
P = 0.05), but the eff  ect size statistic was low (Wn = 0.13), 
suggesting that the two groups had only minimal overall dif-
ferences in HLA types. Moreover, the diff  erences were pri-
marily in unusual alleles, which were each found in only one 
or a few patients. Furthermore, populations of bone marrow 
donors tend to be enriched for more common alleles because 
a match can be more readily found. Therefore, we concluded 
that the overall frequency of HLA-DRB1-DQA1-DQB1 
haplotypes was similar in Lyme arthritis patients and the 
control population.
Haplotype and allele frequencies in Lyme arthritis patients 
by antibiotic response
When the 121 patients with Lyme arthritis were stratifi  ed 
by antibiotic response, 15 DRB1-DQA1-DQB1 haplotypes 
were common enough for individual comparisons (Table I). 
These haplotype frequencies diff  ered signifi  cantly in patients 
with antibiotic-refractory or antibiotic-responsive arthritis 
(log likelihood test, P = 0.009; exact test, P = 0.01; eff  ect 
size, Wn = 0.35). Moreover, when the DRB1 and DQA1-
DQB1 alleles were analyzed separately, the frequencies of the 
DRB1 alleles showed a highly signifi  cant diff  erence (log like-
lihood test, P = 0.006; exact test, P = 0.008) with a large 
  eff  ect size (Wn = 0.38; Table II). The alleles that diff  ered 
most were the DRB1*0101 and 0401 alleles, which were 
more common in antibiotic-refractory patients, and the 0801, JEM VOL. 203, April 17, 2006  963
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Table I.  DRB1-DQA1-DQB1 haplotype frequencies in all patients with Lyme arthritis and in European-American control subjects 
or Lyme arthritis patients stratifi  ed by antibiotic response
DRB1-DQA1-DQB1 Haplotype frequencies G value Haplotype frequencies G value
European-American 
subjectsa
All Lyme arthritis 
patientsb
Lyme arthritis patients
Antibiotic 
refractoryc
Antibiotic 
responsived
%% % %
0101-0101-0501 9.1 7.9 0.4 10.6 4 3.5
0102-0101-0501 1.4 1.7 0.1
0103-0101-0501 0.5 2.1 6.7 0.7 4 3.1
0301-0501-0201 13.1 12.0 0.2 10.6 14 0.6
0401-03-0301 5.4 6.6 0.6 7.7 5 0.7
0401-03-0302 4.9 3.3 1.3 4.9 1 3.2
0402-03-0302 1.0 1.7 0.9
0403-03-0302 0.4 0 1.9
0404-03-0302 3.9 5.0 0.6 5.0 5 0.0
0405-03-0302 0.3 0.8 1.5
0407-03-0301 0.9 1.2 0.3
0701-0201-0202 11.1 9.5 0.5 11.3 7 1.2
0701-0201-0303 3.7 1.2 5.0
0801-0401-0402 2.2 2.9 0.4 0.7 6 5.9
0901-03-0303 0.8 0.4 0.5
1001-0104-0503 0.7 0.0 3.3
1101-0501-0301 5.6 5.4 0 2.8 9 4.1
1103-0501-0301 0.3 0.4 0
1104-0501-0301 2.7 3.3 0.3 0.7 7 7.4
1201-0501-0301 1.1 2.5 2.9 2.8 2 0.2
1301-0103-0603 5.6 3.7 1.6 3.5 4 0.0
1302-0102-0604 3.4 2.5 0.6 2.1 3 0.2
1302-0102-0609 0.7 1.2 0.7
1303-0501-0301 0.7 2.5 5.6 2.1 3 0.2
1305-0501-0301 0.3 0.4 0.2
1401-0104-0503 2.0 1.7 0.1
1501-0102-0602 14.2 10.7 2.1 12.0 9 0.5
1501-0102-0603 2.1 0.8 2.2
1502-0103-0601 0.7 0.8 0.1
1601-0102-0502 1.0 2.1 2.2 2.1 2 0.0
Combinede 1.3 3.7 12.0 20.0
Total 100.0 100.0 42.8 100.0 100.0 30.8
P value 0.05 0.009f
Degree of freedom 29 15
Wn effect size statistic 0.13 0.35
The 42 rare haplotypes that were found only in the control population are not shown here, but a complete listing of haplotypes in the control population has been published 
previously (19). Of the 13 rare haplotypes in patients with Lyme arthritis, 12 (0101-0102-0504, 0403-03-0304, 0408-03-0301, 0409-03-0301, 0416-03-0302, 1102-0501-
0301, 1104-0101-0301, 1104-0103-0603, 1301-0103-0614, 1302-0102-0501, 1401-0104-0502, and 1501-0102-0502) were each found in only one patient, and one (0404-
03-0402) was found in two patients. For comparison of the groups, 1.3% of the haplotypes in normal control subjects and 3.7% of those in all Lyme arthritis patients were 
excluded from analysis. For the analysis of patients by antibiotic response, 12% of those in the refractory group and 20% of those in the responsive group were excluded.
an = 3,798.
bn = 242.
cn = 142.
dn = 100.
eWhen ≤5 individuals with Lyme arthritis or ≤10 individuals in the control population had a given haplotype, the values were excluded from analysis (empty cells).
fFor log likelihood statistic verifi  cation, the 2 × 15 table was also calculated by an exact test; P = 0.01.964  HLA ALLELES IN LYME ARTHRITIS | Steere et al.
  diff  ered most were linked with DRB1 alleles that had even 
greater diff  erences. Thus, several DRB1 alleles accounted 
for most of the diff  erences between antibiotic-refractory and 
antibiotic-responsive patients.
Comparison with past patients
The results in the current 121 patients (seen from 1987 to 
2004) were compared with those in our initial HLA study of 
80 patients with Lyme arthritis (seen from 1977 to 1987; ref-
erence 7). None of the 80 previous patients were included in 
the current study. In the previous analysis, the HLA profi  les 
were determined by serologic typing methods. In addition, 
during the earlier period, we were still learning about the 
cause and treatment of infection. Because some patients were 
not treated with antibiotics and because others received ther-
apy that would be considered inadequate today, the patients 
were stratifi  ed according to the duration of the longest single 
attack of arthritis. Analogous to the current defi  nition  of 
  antibiotic-responsive arthritis, arthritis of ≤3-mo duration in 
past patients was defi  ned as arthritis of brief duration, and, 
similar to the current defi   nition of antibiotic-refractory 
  arthritis, arthritis lasting 4 mo to 4 yr was defi  ned as arthritis 
of moderate or prolonged duration.
When the DRB1 allele subtypes in the current patients 
were combined according to past HLA-DR serologic speci-
fi  cities, arthritis of moderate or prolonged duration in past 
patients and antibiotic-refractory arthritis in the current pa-
tients were both associated primarily with DRB1*04 alleles 
(Table III). In addition, each of the alleles that now make up 
the former DR2 specifi  city was identifi  ed slightly more often 
in past and current patients with more prolonged or antibiotic-
refractory arthritis. Association of the DRB1*0101 molecule 
with antibiotic-refractory arthritis was only apparent in 
  current patients. However, results in the current patients 
  diff  ered according to the subtype: 80% of those with the 
DRB1*0101 allele were in the antibiotic-refractory group; 
those with the DRB1*0102 allele were equally distri  b-
uted between the two groups; and 80% of those with the 
DRB1*0103 allele were in the antibiotic-responsive group 
(P = 0.02). This may have obscured an association in past 
patients. In both past and current patients, alleles that make 
up the former DR5 specifi  city (except for the DRB1*1201 
allele) and the DR3 specifi  city were more common in pa-
tients with arthritis of brief duration or antibiotic-responsive 
arthritis. Thus, although the typing methods and defi  nitions 
for patient stratifi  cation diff  ered in the two studies, similar 
HLA associations were found among the 201 study patients 
with Lyme arthritis tested over a 26-yr period.
OspA peptide binding to HLA-DR molecules
14 recombinant or purifi  ed HLA-DRB1, DRB4, or DRB5 
molecules were available for in vitro peptide binding studies. 
Nearly 80% of the patients had one or two of these DRB 
molecules. Of the 14 molecules, seven showed strong to weak 
binding with the OspA163–175 peptide, whereas the other seven 
showed negligible or no binding of the peptide (Figs. 1 and 2). 
Table II.  DRB1 allele frequencies in patients with 
antibiotic-refractory or antibiotic-responsive Lyme arthritis
DRB1a Allele frequencies G value
Lyme arthritis patients
Antibiotic 
refractoryb
Antibiotic 
responsivec
%%
0101 11.3 4 4.1
0102 1.4 2.0
0103 0.7 4 3.1
0301 10.6 14 0.6
0401 12.7 6 2.8
0402 2.8 0
0403 0.7 0
0404 6.3 6 0.0
0405 1.4 0
0407 2.1 0
0408 0 1
0409 0.7 0
0416 0 1
0701 12.0 9 0.5
0801 0.7 6 5.9
0901 0 1
1101 2.8 9 4.1
1102 0.7 0
1103 0.7 0
1104 1.4 7 5.0
1201 2.8 2 0.2
1301 4.2 4 0.0
1302 2.1 7 3.4
1303 2.1 3 0.2
1401 1.4 3 0.7
1501 14.1 9 1.3
1502 1.4 0
1601 2.1 2 0.0
Combined 7.4 5
Total 100.0 100.0 31.9
P value 0.006a
Degree of freedom 15
Wn effect size 
  statistic
0.38
When less than or equal to fi  ve individuals with Lyme arthritis had a given 
haplotype, the values were excluded from analysis (empty cells). These rare alleles, 
which consisted of 7.4% of the total alleles in the refractory group and 5.0% of 
those in the responsive group, were excluded from the statistical analysis. Rare 
DRB1 alleles and their combined sum are listed in italics.
aFor G statistic verifi  cation, the 2 × 15 table was also calculated by an exact test; 
P = 0.008.
bn = 142.
cn = 100.
1101, 1104, and 1302 alleles, which were more frequent in 
antibiotic-responsive patients. A comparison of the overall 
frequencies of the DQA1-DQB1 alleles alone did not quite 
reach formal statistical signifi   cance (log likelihood test, 
P = 0.07; Wn = 0.27; unpublished data), and the alleles that JEM VOL. 203, April 17, 2006  965
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Table III.  Comparison of HLA-DR specifi  cities and alleles according to disease course in past and current patients with Lyme arthritisa
HLA-DR 
specifi  city
Past patients with 
Lyme arthritis
OR (95% CI) HLA-DRB1 alleles Current patients with 
Lyme arthritis
OR (95% CI)
Moderate or 
prolongedb
Briefc Antibiotic 
refractoryd
Antibiotic 
responsivee
%% % %
DR1 21 18 1.17 (0.35, 3.89) 0101, 0102, 0103 28 18 1.79 (0.75, 4.27)
DR2 41 18 3.18 (0.99, 10.04) 1501, 1502, 1601 32 20 1.92 (0.83, 4.43)
DR3 21 23 0.89 (0.28, 2.77) 0301 20 32 0.51 (0.23, 1.19)
DR4 40 9 6.75 (1.54, ND)f 401/02/03/04/05/06/07/08/
 09/16
46 26 2.47 (1.13, 5.37)
DR5 17 32 0.45 (0.15, 1.34) 1101/02/03/04, 1201 17 36 0.36 (0.16, 0.84)
DR7 14 18 0.72 (0.20, 2.52) 0701 23 18 1.33 (0.54, 3.24)
aThe results in past patients were published previously (7). The 80 patients were stratifi  ed according to the longest single attack of arthritis. Analogous to the current 
defi  nition of antibiotic-responsive arthritis, arthritis of ≤3-mo duration in past patients was defi  ned as arthritis of brief duration, and analogous to the current defi  nition of 
antibiotic-refractory arthritis, arthritis lasting 4 mo to 4 yr in past patients was defi  ned as arthritis of moderate or prolonged duration.
bn = 58.
cn = 22.
dn = 71.
en = 50.
fThe number of patients with the DR4 specifi  city in the brief group was too small to calculate a reliable upper CI.
The DRB1*0401 molecule bound the peptide strongly (half 
maximal MHC–peptide-binding concentration [half max] = 
0.003 μM), the DRB1*0101, 0404, and 0405 molecules 
bound it moderately well (half max = 0.2–0.3 μM), and 
the DRB1*0402 or 0102 molecules bound it weakly (half 
max = 4–6 μM). In addition, separate testing of the  genetically 
Figure 1.  Relative binding avidity of the OspA163–175 peptide to 
seven HLA-DRB molecules that demonstrated strong to weak 
binding of the peptide. The half max binding concentration of the 
B. burgdorferi OspA peptide for each MHC molecule is shown with error 
bars  (SD).  The  sequence  of  the  OspA  peptide  was  K G Y V L E G T L T A E K .  The 
positive control peptide for the B1*0401, 0402, 0404, and 0405 mole-
cules was glutamic acid decarboxylase 65555–567  (N F I R M V I S N P A A T ). 
For the B1*0101 and 0102 molecules, it was artifi  cial peptide-0102 
(P K Y V K L N A L K L A T ),  and  for  the  B5*0101  molecule,  it  was  infl  uenza 
 hemagglutinin307–319  (P K Y V K Q N T L K L A T ).  The  negative  control  peptide  for  the 
B1*0101 and 0102 and B5*0101 molecules was OspA165A  (K G A V L E G T L T A E K ). 
For the B1*0401, 0404, and 0405 molecules, it was retinal S-antigen 
peptide-14  (H V I F K K I S R D K S ),  and  for  the  B1*0402  molecule,  it  was 
Herpes simplex viral protein 1634–44  (P L Y A T G R L S Q A ).  Data  are  not 
  depicted for six HLA-DRB molecules that had negligible binding 
(DRB1*1101; half max = 48 μM) or no detectable binding (half max of 
≥50 μM; DRB1*0301, 0701, 1104, 1501, and DRB4*0101) of the OspA 
peptide. With each of these DRB molecules, the positive control peptide 
showed strong binding, and the negative control peptide showed no 
detectable binding.966  HLA ALLELES IN LYME ARTHRITIS | Steere et al.
linked DRB1*1501/DRB5*0101 molecules showed that 
the DRB5 molecule but not the DRB1 molecule bound the 
peptide moderately well (half max = 0.4 μM).
In contrast, the DRB1*1101 molecule showed negligible 
binding of the peptide (half max = 48 μM), and the 
DRB1*0301 and 1104 molecules and separate testing of 
the genetically linked DRB1*0701/DRB4*0101 molecules 
showed no detectable binding of the peptide (half max of 
≥50 μM; Fig. 2). Although the DRB1*0801 molecule was 
not available for study here, no binding of the OspA peptide 
to this molecule was demonstrated previously when the mol-
ecule was obtained from a homozygous B-lymphoblastoid 
cell line (15). Thus, 40% of the DRB alleles in patients with 
Lyme arthritis showed strong to weak binding of the OspA 
peptide, 39% showed negligible or no binding of the peptide, 
and, for 21% of the alleles, DR molecules were not yet avail-
able for testing.
Correlation of OspA peptide binding 
and HLA-DR frequencies
In general, the DRB molecules that bound the OspA163–175 
peptide were more common in antibiotic-refractory patients, 
whereas those that did not bind it were more frequent in 
  antibiotic-responsive patients (Fig. 2 and Table IV). The ex-
ceptions were the weak OspA peptide–binding DRB1*0102 
molecule, which was found in two patients each with anti-
biotic-refractory or -responsive arthritis, and the genetically 
linked, non-OspA peptide–binding DRB1*0701/DRB4
*0101 molecules, which were found slightly more often in 
the antibiotic-refractory group. Altogether, 79% of the pa-
tients with antibiotic-refractory arthritis had at least one of 
the seven known OspA peptide–binding HLA-DR mole-
cules compared with 46% of those with antibiotic-responsive 
arthritis (odds ratio [OR] = 4.4; P < 0.001; Table IV). 
Moreover, among the subgroup of 31 patients in whom the 
binding potential of both alleles was known, the patients with 
two known OspA peptide–binding alleles were 11.3 times 
more likely to have an antibiotic-refractory course than those 
with two non-OspA peptide–binding alleles (P = 0.008).
Frequencies of RA alleles in Lyme arthritis patients
The severity of RA is associated with DRB1 alleles that have 
a shared sequence in the third hypervariable region of the 
DRB1 chain (20–22). In Caucasian populations, this se-
quence is found most often in the DRB1*0401, 0404, 0405, 
0408, 0101, and 0102 alleles. Except for the 0408 molecule, 
which was not available for testing, these DRB1 molecules 
bound the OspA163–175 peptide. In addition, 43 of the 71 pa-
tients (61%) with antibiotic-refractory Lyme arthritis had one 
or two of these RA alleles compared with 16 of the 50 pa-
tients (32%) with antibiotic-responsive arthritis (OR = 3.3; 
P = 0.004). In a previous analysis (14), PBL from patients 
with RA did not respond to OspA163–175, and, therefore, we 
think that OspA immunity is not a feature of RA. Nevertheless, 
Figure 2.  Correlation of the relative binding avidity of the 
OspA163–175 peptide for 14 HLA-DR molecules with percent allele 
frequencies of these HLA-DR molecules in patients with antibiotic-
refractory or antibiotic-responsive Lyme arthritis. Although the 
DRB1*0801 molecule was not available (NA) for study here, no binding 
of the OspA peptide was demonstrated in a previous analysis in which 
this molecule was obtained from a homozygous B-lymphoblastoid 
cell line (15).JEM VOL. 203, April 17, 2006  967
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primarily DRB1 molecules associated with RA bound 
OspA163–175 and were also associated with antibiotic-refractory 
Lyme arthritis.
DISCUSSION
In this study, we fi  rst compared the frequencies of DRB1- 
DQA1-DQB1 haplotypes in patients with Lyme arthritis 
with those in a Caucasian control population, which did not 
show substantial diff   erences. However, when the patients 
were stratifi  ed by antibiotic response, the two patient groups 
diff  ered. Moreover, this study is unique in examining the 
in vitro binding of a single spirochetal epitope, OspA163–175, 
to recombinant forms of most DRB molecules found in this 
patient population, all of whom had B. burgdorferi infection 
of the joints. When the DRB frequencies and binding 
results were correlated, patients with stronger OspA peptide–
binding DRB molecules were three or four times more likely 
to have antibiotic-refractory arthritis, and those with weaker 
binding molecules were one or two times more likely to have 
this outcome. When the seven known OspA163–175-binding 
DRB alleles were combined, a marked correlation was found 
with antibiotic-refractory arthritis.
Although this series of 121 patients with Lyme arthritis is 
the largest tested to date, the number of patients was not large 
enough to show diff  erences between refractory and respon-
sive patients in the frequencies of individual alleles. More-
over, only small numbers of patients had more unusual alleles, 
some of which bound the OspA163–175 peptide, such as the 
DRB1*0402, 0405, and 0102 molecules. Despite this prob-
lem, groups were analyzed by the log likelihood test because 
it tests the overall diff  erence between two distributions and 
reveals individual contributions to any diff  erence but avoids 
the problem of multiple comparisons when the frequencies 
of alleles or haplotypes are examined individually. However, 
because the number of samples in the tests was relatively 
small, resulting in sparse tables, the log likelihood statistic 
[G value] was verifi  ed by an exact test. Both methods showed 
similar results.
We were able to test OspA163–175 peptide binding of the 
four most common DR4 subtypes (0401, 0404, 0405, and 
0402), each of which showed binding of the OspA peptide 
and would explain the primary association of antibiotic-
  refractory arthritis with DR4 alleles. Among 80 previous pa-
tients, arthritis of moderate or prolonged duration was associated 
primarily with the HLA-DR4 serologic specifi  city (7). In the 
current patients, the DRB1*1501 allele (formerly DR2) was 
slightly more common among antibiotic-refractory patients, 
and, in the previous study, a secondary association was noted 
with the DR2 specifi  city. The OspA peptide binding studies 
would explain this weak association. This peptide does not 
bind the DRB1*1501 molecule but does bind the nearly 
equally expressed DRB5*0101 molecule to which it is linked 
(23, 24). Therefore, additional DRB loci in some HLA class 
II haplotypes may play a critical role in enlarging the peptide-
binding repertoire.
Although the DR1 serologic specifi  city was not increased 
in frequency in the previous study (7), diff  erential binding of 
the OspA peptide to the three DRB1*01 subtypes may ex-
plain this result. Among the current patients, the DRB1*0101 
molecule, which was strongly associated with antibiotic-
refractory arthritis, bound the OspA peptide well. In com-
parison, the DRB1*0102 molecule, which was distributed 
equally between antibiotic-refractory and antibiotic-responsive 
patients, bound the OspA peptide weakly. This molecule 
  diff  ers from the DRB1*0101 molecule in only two amino 
acids (25), which are predicted to make the P1-binding 
pocket smaller (26). This diff  erence would be likely to make 
binding of the OspA peptide’s large aromatic tyrosine in this 
Table IV.  OspA163–175 peptide binding of HLA-DRB1 genotypes in patients with antibiotic-refractory or antibiotic-responsive 
Lyme arthritis
DRB genotypes Number of positive patients OR (95% CI) P value
Antibiotic 
refractory
Antibiotic 
responsive
%%
Two known OspA-binding alleles versus two known nonbinding alleles n = 18 n = 13
  (1) Both alleles bind 15 (83) 4 (31)  11.3 (2.14, 58.8) 0.008
  (2) Neither allele binds   3 (17) 9 (69)
One known OspA-binding allele versus one known nonbinding or 
  unknown binding allele
n = 53 n = 37
  (3) One binding/one non- or unknown binding allelea 41 (77) 19 (51) 3.2 (1.3, 8.0) 0.013
  (4) One nonbinding/one unknown binding allele 12 (23) 18 (49)
All patients n = 71 n = 50
1 and 3: one or two known binding alleles 56 (79) 23 (46)    4.4 (1.99, 9.66) <0.001
2 and 4: no known binding alleles 15 (21) 27 (54)
aAmong the antibiotic-refractory patients, 22 had one known OspA-binding allele and one known non-OspA–binding allele, and 19 had one known OspA-binding allele and 
one allele that was not yet possible to test for binding. Among the antibiotic-responsive patients, 16 had a known OspA-binding allele and one known nonbinding allele, 
and three had one known OspA-binding allele and one allele that was not possible to test for binding.968  HLA ALLELES IN LYME ARTHRITIS | Steere et al.
position less favorable. Compared with the DRB1*0101 
molecule, the DRB1*0103 molecule, which was identifi  ed 
almost exclusively in antibiotic-responsive patients, has three 
amino acid substitutions in the P4 pocket (25), which would 
be likely to alter the peptide-binding properties of that 
  molecule. Thus, small diff  erences in the three quite similar 
alleles of the DR1 specifi  city, leading to diff  erential binding 
of the OspA peptide, would provide an explanation for 
  diff  erences in disease outcomes among these patients.
The antibiotic-refractory group also had a slightly in-
creased frequency of the genetically linked DRB1*0701/
DRB4*0101 molecules, neither of which bound the OspA 
peptide. In the previous study (7), no association was seen 
between the duration of arthritis and the DR7 specifi  city. 
Because all of the current DRB1-0701–positive, antibiotic-
refractory patients had the linked DQB1*0202 molecule, it 
is possible that this molecule or a linked DP molecule may 
bind the OspA peptide weakly, but we are not yet able to test 
this hypothesis. Alternately, the slightly increased frequency 
of these molecules in the current patients may have occurred 
by chance.
Might another spirochetal epitope show a similar or even 
better correlation between DRB frequencies and peptide 
binding? The B. burgdorferi genome contains sequences for 
1,639 known or predicted proteins (27, 28), and a given 
  protein may have as many as seven predicted T cell epitopes. 
In a recent computer search, the closest match with OspA163–175 
was an epitope of B. burgdorferi glycerol kinase, which 
  contained the OspA epitope’s fi  rst  fi   ve core amino acids 
(YVLEG). However, the glycerol kinase epitope did not 
stimulate patients’ T cells (unpublished data). We also identi-
fi  ed predicted T cell epitopes of 10 known immunogenic 
proteins of B. burgdorferi and selected eight epitopes for 
binding studies. The OspA163–175 peptide and one epitope of 
  fi  bronectin-binding protein (BBK32392–404) had similar binding
patterns, and BBK32392–404 even showed weak binding of the 
DRB1*0701 and DRB4*0101 molecules. However, patients’ 
T cells did not respond to the BBK32 epitope (unpublished 
data). Finally, Lyme borreliosis worldwide is caused by three 
related pathogenic Borrelia species: B. burgdorferi, B. afzelii, and 
B. garinii (29). In a recent study, the sequences of the core 
OspA165–173 epitope diff  ered among the three species, and 
lymphocytes from patients with antibiotic-refractory Lyme 
arthritis proliferated only in response to the B. burgdorferi 
  peptide (30). Thus, we have not yet found a borrelial epitope 
other than OspA163–175 that shows a correlation with 
the HLA data and is preferentially recognized by T cells in 
antibiotic-refractory patients (16, 17).
Four basic hypotheses have been proposed to explain the 
association of OspA163–175 peptide–binding DRB alleles with 
antibiotic-refractory Lyme arthritis: (a) persistent infection, 
(b) retained spirochetal antigens, (c) infection-induced auto-
immunity resulting from molecular mimicry between a spi-
rochetal and host epitope, or (d) from bystander activation of 
autoreactive T cells (31). According to the persistent infection 
hypothesis, an HLA-linked immune response to B. burgdorferi 
in antibiotic-refractory patients may be ineff  ective in eradicating 
spirochetes from a protected niche in the joint even though 
these patients have higher levels of IFN-γ, TNF-α, and other 
proinfl  ammatory cytokines in infected joints than antibiotic-
responsive patients (Shin, J.J., L.J. Glickstein, G. McHugh, 
and A.C. Steere. 13th Annual Conference of the Interna-
tional Cytokine Society. 2005. Abstr. P3-60; Fawcett, P.T., 
C.D. Rose, V.L. Maduskuie, J.J. Sanderson, P.A. Stanek, 
T. Stetson, A. Brescia, and L.B. Fawcett. 2005. Annual Meeting 
of the American College of Rheumatology. Abstr. 172). 
In that case, a preferential T cell response to OspA163–175, 
a protein expressed only in infl  amed joints (13), may simply 
be a marker for more prolonged infection in refractory than 
responsive patients. However, if small numbers of spirochetes 
remain in the synovial tissue of refractory patients, they are 
below the limits of detection by PCR because PCR results 
have been uniformly negative in their synovectomy samples 
(6). Alternately, MHC molecules in synovial tissue may pref-
erentially retain OspA antigens after spirochetal killing, and 
T cell recognition of these antigens, along with high levels 
of proinfl   ammatory cytokines (Shin, J.J., L.J. Glickstein, 
G. McHugh, and A.C. Steere. 13th Annual Conference of 
the International Cytokine Society. 2005. Abstr. P3-60; 
Fawcett, P.T., C.D. Rose, V.L. Maduskuie, J.J. Sanderson, 
P.A. Stanek, T. Stetson, A. Brescia, and L.B. Fawcett. 2005. 
Annual Meeting of the American College of Rheumatology. 
Abstr. 172), may continue to induce synovial infl  ammation 
for months after spirochetal killing.
According to the molecular mimicry hypothesis of auto-
immunity, molecular mimicry between the OspA163–175 epit-
ope and a similar sequence of a self protein might serve as a 
bridge to activate an autoimmune T cell or linked B cell re-
sponse within the proinfl  ammatory milieu of infl  amed joints 
(31). We originally proposed human LFA-1αL332–340, which 
has partial sequence homology with OspA163–175, as a candi-
date autoantigen in antibiotic-refractory Lyme arthritis (14). 
However, we later showed that the LFA-1 peptide was only 
a weak, partial agonist for OspA163–175-reactive T cells (32), 
and the LFA-1 peptide does not bind the refractory arthritis-
associated DRB1*0101 molecule (15). Thus, we now think 
that this peptide is unlikely to be a relevant autoantigen. 
  Although it has been a formidable challenge to identify rele-
vant infectious and self molecular mimics in any disease, the 
association of antibiotic-refractory Lyme arthritis with a single 
spirochetal epitope could still be explained by such a mecha-
nism, which may depend on structural similarity between 
OspA163–175 and a self epitope rather than simple sequence 
similarity (33). Alternately, T cell recognition of the OspA163–175 
epitope in genetically susceptible individuals may lead to 
  especially high levels or inadequate regulation of proinfl  am-
matory cytokines, which might cause T cell activation to 
a structurally unrelated or shielded self epitope. However, 
recognition of the OspA epitope alone is clearly insuffi   cient 
to induce disease because among nearly 10,000 individuals 
vaccinated with OspA in the deltoid muscle, autoimmune 
arthritis was not observed (34, 35). Recognition of the epitope JEM VOL. 203, April 17, 2006  969
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within the proinfl  ammatory milieu of infected joints would 
presumably be necessary.
Regardless, we do not think that a single mechanism 
  explains persistent arthritis after 2–3 mo of antibiotic therapy 
in all patients. Although most of the antibiotic-refractory 
  patients who lacked one of the seven known OspA peptide–
binding DR molecules had molecules that are not yet available 
in recombinant form for in vitro studies, three patients had 
two alleles that are known not to bind this peptide. More-
over, after the clinical classifi  cation was made, it became clear 
that at least one patient classifi   ed in the refractory group 
still had persistent infection. The patient, who had the 
DRB1*0301 and 1302 alleles and lacked OspA reactivity, 
had the resolution of arthritis 6 mo after the initiation of a 
2-mo course of oral antibiotic therapy. Later, she had two 
  recurrences of arthritis, and the fi  rst was accompanied by a 
positive PCR result for B. burgdorferi DNA in joint fl  uid. 
Nevertheless, for this study, we retained the initial classifi  cation 
of each patient, which was made before HLA typing. We 
would emphasize that the inclusion of such patients would 
bias against showing an association between antibiotic-refractory 
arthritis and OspA163–175-binding DRB alleles, yet an association 
was still demonstrated.
It is of great interest that primarily DRB1 molecules asso-
ciated with RA bound OspA163–175 and were also associated 
with antibiotic-refractory Lyme arthritis. However, several 
non-RA–associated DRB1 molecules also bound the OspA 
peptide, including the DRB1*0402 and DRB5*0101 mole-
cules, and RA patients’ PBLs did not respond to the OspA 
peptide (14). Although OspA immunity is not a feature of 
RA, the similar HLA associations in both diseases raise the 
possibility that specifi  c HLA molecules or other HLA-linked 
immune responses, such as TNF-α levels, are important in 
the pathogenesis of both diseases.
In conclusion, we found a marked association between 
antibiotic-refractory Lyme arthritis and DRB molecules that 
bound the OspA163–175 epitope of B. burgdorferi. This clinical 
correlation suggests that binding of a single spirochetal pep-
tide, OspA163–175, to certain DRB molecules, primarily those 
associated with RA, is a marker for antibiotic-refractory 
Lyme arthritis and might play a role in the pathogenesis of 
the disease.
MATERIALS AND METHODS
Study patients. From August 1987 through May 2004, we evaluated 121 
consecutive patients with Lyme arthritis (ages 12–79) who were treated with 
antibiotics according to the guidelines now recommended by the Infectious 
Diseases Society of America (18). The study protocol, which included HLA 
typing, was approved by the Human Investigations Committees at Tufts-
New England Medical Center (1987–2002), Massachusetts General Hospital 
(2002–2004), and the University of California, San Francisco (1999–2004); 
all patients gave written informed consent. All patients met the criteria of the 
Centers for Disease Control for the diagnosis of Lyme arthritis (36, 37).
50 patients (41%) had antibiotic-responsive arthritis, which was defi  ned, 
as in previous studies (15, 16), as the resolution of arthritis within 3 mo after 
the start of no more than 4 wk of i.v. antibiotics or 8 wk of oral antibiotics. 
In this group, the median duration of antibiotic therapy was 4 wk (range of 
4–8 wk), and the median duration from the start of antibiotics to the resolution 
of arthritis was also 4 wk (range of 2–11 wk). The remaining 71 patients 
(59%) had antibiotic-refractory arthritis, which was defi  ned as persistent joint 
swelling for ≥3 mo after the start of ≥4 wk of i.v. antibiotics, ≥8 wk of oral 
antibiotics, or both. Their median duration of antibiotic therapy was 13 wk 
(range of 4–29 wk), and the median duration from antibiotic initiation to 
  arthritis resolution was 11 mo (range of 4–48 mo).
Of the 55 patients who were referred before or during their fi  rst 
course of antibiotics, 50 (91%) had antibiotic-responsive arthritis, and fi  ve 
had an antibiotic-refractory course, a distribution similar to that found in 
the community (3). The remaining 66 study patients were fi  rst referred to 
us later in their course because of a lack of response to antibiotics. Thus, 
this distribution of refractory and responsive cases is refl  ective of our role 
as a referral center.
HLA typing procedures. HLA-DRB1, DQA1, and DQB1 alleles in the 
121 patients were determined by high resolution molecular HLA typing 
methods using sequence-specifi   c oligonucleotide probes, automated se-
quencing, or sequence-specifi  c priming (Dynal) as previously described (38). 
In 1992, HLA typing was determined in patients seen in the previous 5 yr; 
thereafter, typing was determined on a yearly basis. Although typing meth-
ods were modifi  ed during the study as new typing techniques became avail-
able, the typing methods used throughout the study were capable of resolving 
the more common HLA alleles.
Production of recombinant HLA-DR molecules and peptides. 
  Recombinant, soluble HLA-DR molecules were generated from Schneider 
S-2 cells that expressed the extracellular domains of DRα and DRβ chains 
linked to the leucine zipper dimerization domains of the transcription factors 
c-Fos and c-Jun, respectively (39). The transfected cells were expanded to 
a density of 4–6 × 106 cells/ml, and 1 mM CuSO4 was added to induce 
production of the soluble class II molecules. Recombinant MHC molecules 
were purifi   ed by affi     nity chromatography using the HLA-DR–specifi  c 
monoclonal antibody L243 (40). The peptides were synthesized and biotin-
ylated as previously described (40). Two aminohexanomic acid spacers were 
placed between the biotin and peptide to inhibit steric hindrance.
MHC–peptide-binding assay. One 96-well plate (Costar) was coated 
with 100 μl (12.5 μg/ml) of the anti-DR monoclonal antibody L243 diluted 
in 12.5 mM borate buff  er and incubated overnight at 4°C as previously 
  described (15). In a second plate (Costar), 1 μl (50 μM) of each biotinylated 
peptide diluted in DMSO (Sigma-Aldrich) was placed in duplicate wells; 
200 μl of purifi  ed MHC molecules (0.004 μg/ml) diluted in citrate phos-
phate buff  er, pH 5.4, with 0.75% n-octyl-β-D-glucopyranoside (Sigma-
  Aldrich) and 1 mM PefaBloc (Roche) were then added to each well and 
incubated overnight at 37°C in a humidifi  ed chamber. The following day, 
the antibody plate was washed fi  ve times with 0.05% Tween-20 in PBS, pH 
7.4, and blocked with 5% FCS in PBS for 3 h at room temperature. After 
washing, 50 μl of 50 mM Tris, pH 8.0, with 0.75% n-octyl-β-D-glucopy-
ranoside was added to each well, and MHC–peptide complexes were trans-
ferred to the antibody plate and incubated overnight at 4°C. The following 
day, 0.1 mg/ml europium-labeled streptavidin diluted in assay buff  er was 
added to each well and incubated for 30 min at room temperature followed 
by enhancement buff  er (each from PerkinElmer) for 10–15 min. Fluores-
cence was then measured with a multilabel counter (Victor2 1420; PerkinElmer). 
The half max binding concentration of OspA163–175 was defi  ned as the 
  concentration of OspA peptide required for the binding of half of the MHC 
molecules compared with the positive control peptide.
Statistical analysis. The frequency of haplotypes and alleles in all patients 
with Lyme arthritis and control subjects and in Lyme arthritis patients strati-
fi  ed by antibiotic response were fi  rst compared by means of a 2 by k test for 
homogeneity. The overall deviations between the two frequency distribu-
tions were calculated with the G value, and the sum of the individual G val-
ues was used to evaluate the overall diff  erence between the two distributions 
(41). Because the number of samples in the tests was relatively small,   resulting 970  HLA ALLELES IN LYME ARTHRITIS | Steere et al.
in sparse tables, the G statistic was verifi  ed by an exact test on the 2 by k 
  distribution of the observed counts using the R language library Fisher test. 
The eff  ect size statistic, Wn, a chi square–related statistic that ranges from 0 
(no overlap) to 1 (complete identity), was also calculated as a measure of 
the absolute diff  erences between the comparison groups (42, 43). For the 
comparisons of DR alleles with specifi  cities and of OspA163–175-binding or 
nonbinding DRB molecules in antibiotic-responsive or -refractory patients, 
ORs (cross product ratios) and 95% confi  dence intervals (CIs) were calcu-
lated. P values for the comparisons of patient frequencies were calculated by 
two-tailed exact tests.
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